{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T19:18:05Z","timestamp":1780082285845,"version":"3.54.0"},"reference-count":16,"publisher":"S. Karger AG","issue":"3","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuroepidemiology"],"published-print":{"date-parts":[[2013]]},"abstract":"<jats:p>&lt;b&gt;&lt;i&gt;Objectives:&lt;\/i&gt;&lt;\/b&gt; To compare the incidence of cardiac and cerebrovascular events following non-arteritic anterior ischemic optic neuropathy (NAION) compared to published control data using the Framingham, United Kingdom Prospective Diabetes Study (UKPDS) and the National Vascular Disease Prevention Alliance (NVDPA) data. &lt;b&gt;&lt;i&gt;Methods:&lt;\/i&gt;&lt;\/b&gt; A retrospective study of all consecutive cases of NAION between 1990 and 2005. Patients were stratified into those with or without prior ischemic events and into diabetics and non-diabetics. Outcome measures included cardiovascular morbidity, cerebrovascular events and the Framingham, UKPDS and NVDPA scores for each patient. &lt;b&gt;&lt;i&gt;Results:&lt;\/i&gt;&lt;\/b&gt; According to the NVDPA, the average absolute 5-year risk for cardiovascular disease (CVD) was 8.98, compared to 9 CVD events in our study. In the diabetic patients, 5 (17%) had a cardiac event and 2 (8%) had a cerebral vascular accident (CVA). Based on the UKPDS risk calculator, the average 10-year risk for cardiac events is 21.6%, CVA \u20136.8%. In the non-diabetics, there were 3 cases (7.5%) of myocardial infarction, compared to the average 10-year Framingham risk for myocardial infarction or coronary death of 11% (\u00b18 SD). &lt;b&gt;&lt;i&gt;Conclusions:&lt;\/i&gt;&lt;\/b&gt; Following NAION, the incidence of cardiovascular or cerebrovascular events in patients taking aspirin is not in major excess from that expected in risk-factor age-matched controls.<\/jats:p>","DOI":"10.1159\/000342155","type":"journal-article","created":{"date-parts":[[2013,1,25]],"date-time":"2013-01-25T07:09:32Z","timestamp":1359097772000},"page":"220-224","source":"Crossref","is-referenced-by-count":12,"title":["Do Patients with Non-Arteritic Ischemic Optic Neuritis Have Increased Risk for Cardiovascular and Cerebrovascular Events?"],"prefix":"10.1159","volume":"40","author":[{"given":"Murat","family":"Hasanreisoglu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eyal","family":"Robenshtok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ezrahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadas","family":"Stiebel-Kalish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2013,1,24]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097%2F00019052-200402000-00006"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097%2F00041327-200306000-00012"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001%2Farchopht.1996.01100140566007"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093%2Fbrain%2F98.4.689"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001%2Farchopht.1997.01100160573008"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097%2F00041327-200503000-00006"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016%2FS0161-6420%2899%2990563-8"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016%2FS0002-9394%2802%2901639-2"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001%2Farchopht.1985.01050080048018"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136%2Fjnnp.53.10.830"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038%2Feye.1999.90"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001%2Fjama.286.2.180"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1525-1497.2003.30107.x"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1161%2F01.STR.0000020091.07144.C7"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1042%2FCS20000335"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016%2F1047-2797%2893%2990100-I"}],"container-title":["Neuroepidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/342155","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/342155","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T18:44:31Z","timestamp":1745433871000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000342155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":16,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2013,3,1]]},"published-print":{"date-parts":[[2013,3,26]]}},"URL":"https:\/\/doi.org\/10.1159\/000342155","archive":["Portico"],"relation":{},"ISSN":["0251-5350","1423-0208"],"issn-type":[{"value":"0251-5350","type":"print"},{"value":"1423-0208","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}